Welcome to our dedicated page for 180 Life Sciences news (Ticker: ATNF), a resource for investors and traders seeking the latest updates and insights on 180 Life Sciences stock.
180 Life Sciences Corp. Common Stock (symbol: ATNF) represents a pioneering clinical-stage biotechnology company based in Menlo Park, California. The company focuses on developing innovative therapeutics to address unmet medical needs in chronic pain, inflammation, and fibrosis.
The company has several key product development platforms currently in Phase IIb/III clinical trials:
- Fibrosis and Anti-TNF Platform: This platform targets the treatment of fibrosis and anti-tumor necrosis factors, a major cause of inflammation.
- Synthetic Cannabidiol (CBD) Analogs Platform: This platform includes man-made derivatives of CBD designed to offer therapeutic benefits.
- α7nAChR Platform: Focused on the alpha 7 nicotinic acetylcholine receptor, which plays a role in modulating inflammation and pain.
180 Life Sciences Corp. is committed to advancing its drug candidates through robust clinical trials and cutting-edge research. From addressing postoperative pain relief with orally absorbed CBD tablets to combating chronic inflammation and fibrosis, the company's innovative approach highlights its significance in the biotechnology landscape.
The company’s recent achievements include a notable presentation by Dr. Michael J. Alaia at the 2022 American Academy of Orthopaedic Surgeons Annual Meeting. The talk focused on the efficacy of CBD tablets for postoperative pain relief, showcasing the potential impact of 180 Life Sciences Corp.'s therapies.
For more information, investors can contact Jason Assad, Director of Investor Relations, at jassad@180lifesciences.com.
180 Life Sciences (NASDAQ: ATNF) has announced a global licensing agreement with The University of Oxford for the development of HMGB1, a regenerative molecule aimed at promoting liver repair. The agreement involves a small upfront fee with additional payments contingent on clinical milestones. This initiative targets liver disorders such as NASH, a condition with no approved therapies. The collaboration aims to advance GMP production and safety testing in preparation for an Investigational New Drug application.
180 Life Sciences Corp. (NASDAQ: ATNF) announced positive top-line results from its Phase 2b clinical trial for Dupuytren’s disease, demonstrating significant reductions in nodule hardness and size. The trial met both primary and secondary endpoints, showing high patient compliance without serious adverse events. Although detailed data cannot be released due to publication policies, the Company anticipates commercialization discussions with regulatory bodies in 2022. 180 Life Sciences aims to lead in fibrosis therapies, with no current competitors for early-stage Dupuytren’s disease treatments.
180 Life Sciences Corp. (NASDAQ: ATNF) announced a keynote by Professor Jagdeep Nanchahal at the 2021 International Dupuytren Symposium on December 1, 2021. The presentation focused on re-purposing anti-TNF for Dupuytren’s disease and disclosed promising phase 2b clinical trial results. The trial met primary and secondary endpoints, showing significant improvement in nodule hardness and size, with no severe adverse events reported. The full results are pending publication in a peer-reviewed journal, indicating a potential new therapeutic approach for Dupuytren’s disease.
180 Life Sciences Corp. (ATNF) announced the extension of its patent portfolio with new patents granted in the US and Canada for methods treating chronic pain using specific phenyl substituted cyclohexenyl compounds related to cannabidiol (CBD). These patents complement existing protections in Europe, China, and Israel. The company is focusing on synthetic cannabidiol analogues aimed at improving pain management for patients with rheumatoid arthritis. CEO Dr. James Woody noted the potential of these compounds to address unrelieved pain in patients not responding to current therapies.
180 Life Sciences Corp. (NASDAQ: ATNF) announced that Professor Jagdeep Nanchahal will present a keynote on ‘Re-purposing anti-TNF for Dupuytren’s Disease’ at the 2021 International Dupuytren Symposium on December 1, 2021. He will discuss the molecular mechanisms of Dupuytren’s disease and share data from phase 2a and 2b clinical trials. Additionally, the company anticipates starting a frozen shoulder clinical trial in early 2022. 180 Life Sciences is focusing on innovative drug development for unmet needs in inflammatory diseases and fibrosis.
180 Life Sciences Corp. (NASDAQ: ATNF) has appointed Quan A. Vu as Chief Operating Officer/Chief Business Officer. With 20 years in biopharma, Vu has a strong track record in corporate development and negotiations, previously working with companies like Aegis Therapeutics and Sanofi. CEO Dr. James Woody expressed confidence in Vu's ability to enhance the company's drug development efforts. 180 Life Sciences focuses on innovative therapies for inflammatory diseases, leveraging expertise from renowned universities.
180 Life Sciences Corp. (NASDAQ: ATNF) announced the publication of a pre-clinical study on CBG (cannabigerol) derivatives, demonstrating their potential to treat pain, inflammation, and obesity. Conducted in collaboration with experts from Hebrew University and Oxford University, the study highlighted HUM-234's ability to prevent weight gain and improve liver health in high-fat diet mice. The findings support the therapeutic promise of CBG derivatives, with implications for addressing metabolic disorders. The report strengthens the company's position in developing non-psychoactive drugs targeting inflammation and related conditions.
180 Life Sciences (NASDAQ: ATNF) announced it received a Notice of Allowance for its patent application 16/661,769 regarding a method to reduce Post-Operative Cognitive Dysfunction (POCD). This patent comes as a result of innovative research highlighting that administration of anti-TNF antibodies before surgery may lower the risk of delirium in elderly patients post-hip surgery. There are currently no approved treatments for POCD. The company is collaborating with the University of Oxford on a randomized controlled trial to validate these findings and improve patient outcomes.
180 Life Sciences Corp. (NASDAQ: ATNF) announced a Memorandum of Understanding with Celltrion Healthcare for the supply of anti-TNF biosimilar drugs. This collaboration aims to develop anti-TNF therapies for new indications, specifically targeting unmet medical needs in early-stage Dupuytren’s disease, frozen shoulder, and post-operative cognitive deficit. CEO Dr. James Woody expressed optimism about the partnership, anticipating a binding Letter of Intent soon. 180 Life Sciences is also progressing with clinical trials for its candidates, aiming to address significant health challenges.
180 Life Sciences Corp. (NASDAQ: ATNF) announced significant progress in its operations and upcoming clinical trials in a letter from CEO Dr. James Woody. The company recently completed a $15M private placement, enhancing its financial standing to accelerate clinical programs for conditions like Dupuytren's contracture and frozen shoulder. All legacy liabilities from previous mergers have been addressed, allowing for timely financial reporting and compliance with Nasdaq. The firm also expanded its board with experienced professionals to bolster its strategic direction and execution.
FAQ
What is the current stock price of 180 Life Sciences (ATNF)?
What is the market cap of 180 Life Sciences (ATNF)?
What does 180 Life Sciences Corp. specialize in?
Where is 180 Life Sciences Corp. headquartered?
What are the key platforms of 180 Life Sciences Corp.?
What stage are the company's product development platforms in?
Who can be contacted for investor relations?
What is the focus of the recent talk presented by Dr. Michael J. Alaia?
What is the company's ticker symbol?
What unmet medical needs does 180 Life Sciences Corp. aim to address?
What is the significance of the α7nAChR platform?
How can I stay updated with the latest news about 180 Life Sciences Corp.?
